D3 and 5-ht2a receptor modulators

A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I

• wherein:
• X is independently halogen or C1-6-alkyl;
• n is 0, 1, or 2;
• R1 is —COR2 or —SO2—C1-6-alkyl;
• R2 is C1-6-alkyl, C1-6-haloalkyl, C1-6-hydroxyalkyl, C1-6-alkoxy, 3 to 10 membered cycloalkyl, 4 to 10 membered heterocycloalkyl, or 5 to 10 membered heteroaryl, which are each optionally substituted by one or more substituents selected from the group consisting of:
• halo,
• hydroxy,
• C1-6-alkyl,
• C1-6-haloalkyl,
• C1-6-hydroxyalkyl,
• C1-6-alkoxy,
• C1-6-alkoxy optionally substituted by one or more Ra,
• —S—C1-6-alkyl,
• —SO2—C1-6-alkyl,
• —CONH2,
• —CHO,
• 3 to 10 membered cycloalkyl optionally substituted by one or more Ra,
• 4 to 10 membered heterocycloalkyl optionally substituted by one or more Ra, and
• 5 to 10 membered heteroaryl optionally substituted by one or more Ra;
• wherein Ra is selected from the group consisting of:
• halo,
• hydroxy,
• C1-6-alkyl,
• C1-6-hydroxyalkyl,
• C1-6-haloalkyl, and
• C1-6-alkoxy;
• or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.